<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00635973</url>
  </required_header>
  <id_info>
    <org_study_id>1839IL/0026</org_study_id>
    <secondary_id>D7913C00026</secondary_id>
    <nct_id>NCT00635973</nct_id>
  </id_info>
  <brief_title>Open-Label Extension of Other SZ1839 (Iressa) Trials</brief_title>
  <official_title>Multi-Centre, Open-Label Extension Trial of Treatment With ZD1839 (Iressa) in Patients Who Have Been Treated in Other ZD1839 Clinical Trials and May Benefit From Continued Monotherapy ZD 1839.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A trial to assess patients who have been treated with Iressa in a previous clinical trial and
      may benefit from continued treatment with Iressa.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Every 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Every 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Every 28 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib (Iressa)</intervention_name>
    <description>Iressa</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Received treatment in a previous Iressa clinical trial

          -  Provided Informed Consent to participate in the trial

          -  30 days or less since completing the previous Iressa trial.

        Exclusion Criteria:

          -  Radiotherapy completed more than 14 days before starting treatment in this trial

          -  Incomplete healing from prior surgery

          -  Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2008</study_first_submitted>
  <study_first_submitted_qc>March 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2008</study_first_posted>
  <last_update_submitted>April 21, 2009</last_update_submitted>
  <last_update_submitted_qc>April 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Alison Armour Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Iressa</keyword>
  <keyword>Gefitinib</keyword>
  <keyword>Cancer</keyword>
  <keyword>Patients diagnosed with cancer who have previously received Iressa in an Iressa clinical trial</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

